

Research article

Open Access

Molecular epidemiology of pneumococci obtained from Gambian children aged 2–29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine

Martin Antonio*¹, Hannah Dada-Adegbola¹, Ekow Biney¹, Tim Awine¹, John O'Callaghan¹, Valentin Pfluger², Godwin Enwere¹, Brown Okoko¹, Claire Oluwalana¹, Adeola Vaughan¹, Syed MA Zaman¹, Gerd Pluschke², Brian M Greenwood³, Felicity Cutts¹ and Richard A Adegbola¹

Address: ¹Medical Research Council Laboratories, Banjul, The Gambia, ²Swiss Tropical Institute, Basel, Switzerland and ³London School of Hygiene and Tropical Medicine, UK

Email: Martin Antonio* - mantonio@mrc.gm; Hannah Dada-Adegbola - dadaadegbola@yahoo.com; Ekow Biney - ekowbee746@yahoo.com; Tim Awine - TAwine@navrongo.mimcom.net; John O'Callaghan - ocallaghan.john@gmail.com; Valentin Pfluger - V.Pflueger@stud.unibas.ch; Godwin Enwere - genwere@mrc.gm; Brown Okoko - bokoko@mrc.gm; Claire Oluwalana - colulana@mrc.gm; Adeola Vaughan - ade_vaughan@hotmail.com; Syed MA Zaman - azaman228@yahoo.com; Gerd Pluschke - gerd.pluschke@unibas.ch; Brian M Greenwood - Brian.Greenwood@lshtm.ac.uk; Felicity Cutts - Felicity.Cutts@lshtm.ac.uk; Richard A Adegbola - radegbola@mrc.gm

* Corresponding author

Published: 11 June 2008

Received: 13 September 2007

BMC Infectious Diseases 2008, 8:81 doi:10.1186/1471-2334-8-81

Accepted: 11 June 2008

This article is available from: <http://www.biomedcentral.com/1471-2334/8/81>

© 2008 Antonio et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The study describes the molecular epidemiology of *Streptococcus pneumoniae* causing invasive disease in Gambian children

Methods: One hundred and thirty-two *S. pneumoniae* isolates were recovered from children aged 2–29 months during the course of a pneumococcal conjugate vaccine trial conducted in The Gambia of which 131 were characterized by serotyping, antibiotic susceptibility, BOX-PCR and MLST.

Results: Twenty-nine different serotypes were identified; serotypes 14, 19A, 12F, 5, 23F, and 1 were common and accounted for 58.3% of all serotypes overall. MLST analysis showed 72 sequence types (STs) of which 46 are novel. eBURST analysis using the stringent 6/7 identical loci definition, grouped the isolates into 17 clonal complexes and 32 singletons. The population structure of the 8 serotype 1 isolates obtained from 4 vaccinated and 2 unvaccinated children were the same (ST 618) except that one (ST3336) of the isolates from an unvaccinated child had a novel ST which is a single locus variant of ST 618.

Conclusion: We provide the first background data on the genetic structure of *S. pneumoniae* causing IPD prior to PC7V use in The Gambia. This data will be important for assessing the impact of PC7V in post-vaccine surveillance from The Gambia.

Background

Pneumonia is a frequent cause of childhood deaths in many developing countries and its leading cause is *Streptococcus pneumoniae* [1-3]. In The Gambia, there is a high burden of pneumococcal disease in young children in both urban and rural settings [4-9]. During a recently concluded pneumococcal conjugate vaccine trial in The Gambia, the incidence of invasive pneumococcal disease in children who had not received the vaccine was 363 (95% CI 157, 715) per 100 000 person-years in children aged 6 weeks to 5 months and 576 (95%CI 369, 857) per 100,000 person years in those aged 6–11 months [7]. Similar figures have been reported from rural Kenya in a population that had not received Hib or pneumococcal conjugate vaccines [10]. The pneumococcus is also a major cause of otitis media, responsible for much morbidity in young children worldwide [11]. HIV infection increases susceptibility to pneumococcal infection and, as a consequence, the incidence of pneumococcal infection in children and adults is increasing in many parts of sub-Saharan Africa [12,13]. Emergence of antibiotic resistant pneumococci has complicated case-management strategies for pneumococcal disease. Therefore, long-term prevention of pneumococcal disease in young children by vaccination is a major international public health priority.

S. pneumoniae is subdivided into 91 different serotypes [14], all of which are capable of causing invasive disease. Geographic variations in the distribution of pneumococcal serotypes exist and some serotypes are associated selectively with disease in children or adults [15]. The advent of pneumococcal conjugate vaccines provides a potential way of preventing pneumococcal disease although available vaccines contain only a limited number of serotypes. The results of a recently concluded efficacy trial of a 9-valent pneumococcal conjugate vaccine (Wyeth) in Basse, a typical rural African setting in The Gambia, are highly encouraging as they showed protective efficacies, among children who received three doses of vaccine according to protocol, of 37% against radiological pneumonia, 77% against invasive pneumococcal disease of vaccine serotype, 50% against overall pneumococcal disease, 15% against all-cause hospitalizations and 16% against all-cause mortality [16]. The licensed 7-valent pneumococcal conjugate vaccine (Prevenar®) has had a dramatic impact on the incidence of invasive pneumococcal disease in vaccinated infants in the United States and has also protected unvaccinated adults through the induction of herd protection [17]. However, concerns have been raised about the long terms effects of vaccines containing limited numbers of serotypes on the overall pneumococcal population [17]. Thus, prior to the planned introduction of Prevenar® into the routine immunisation programme of The Gambia, we studied 131 but presented data on 127 *S. pneumoniae* isolates obtained from vaccinated or unvaccinated

children (<2 years old) during The Gambian vaccine trial (between August 2000 and April 2004) by BOX-PCR genotyping and MLST to determine the current population structure of pneumococci in the country.

Methods

Study population

Seven thousand, five-hundred and fifty-nine samples including blood (6964), CSF (242), lung aspirate (123) or pleural effusion (230) were obtained from 4,944 children investigated for possible invasive pneumococcal disease during the course of a 9-valent pneumococcal conjugate vaccine trial (PCV9) conducted in The Gambia [7,16]. When more than one isolate was obtained during a single episode of illness, for example from blood and CSF, multiple isolates have been included in the analysis only if they differed by MLST and/or antibiotic susceptibility pattern. Only one child had two episodes of illness. One pneumococcal isolate was not viable after freezing and has not been tested further. Consequently, 132 *S. pneumoniae* isolates were recovered from vaccinated and unvaccinated children aged 2–29 months during the course of a pneumococcal conjugate vaccine trial conducted in The Gambia of which 131 were characterized by serotyping, antibiotic susceptibility, BOX-PCR and MLST and 127 had unique MLST and/or antibiotic susceptibility pattern and were included in this study. Details of how children were enrolled, followed up and investigated have been described previously [7,16]. Written consent was obtained from the parents and the trial was approved by the Joint Gambia Government and MRC Ethics Committee and Ethics Committees at the London School of Hygiene & Tropical Medicine and the World Health Organization.

Isolation and serotyping of *S. pneumoniae*

S. pneumoniae isolates were obtained from lung aspirate, blood, CSF, pus or pleural fluid using an automated culturing system and/or by direct plating onto solid blood agar plates at the patient's bedside as previously described [7,16]. Pneumococci were serotyped initially by latex agglutination in The Gambia; serotype identification was subsequently confirmed using capsular swelling (Quellung reaction) at the Health Protection Agency (HPA) laboratory in Colindale, UK, using commercially available antisera (Statens Serum Institute, Copenhagen, Denmark) as described previously [7,16].

Antimicrobial susceptibility testing

Antimicrobial susceptibility was determined by measurement of the minimum inhibitory concentration (MIC). MIC of each isolate was tested by E-strips (AB Biodisk, Solna, Sweden) following the manufacturer's instructions. The E-strips used tested for penicillin G, chloramphenicol, ampicillin, tetracycline, cefotaxime and cotrimoxazole sensitivity. *S. pneumoniae* ATCC 49619 strain was used as

a control and data were interpreted as susceptible, intermediate or resistant following the manufacturer's instructions.

The MRC microbiology laboratory submits to the external quality assurance programme of the United Kingdom National External Quality Assessment Service [18]

BOX PCR genotyping

Pneumococcal strain typing by BOX-PCR was performed as described previously [19] with slight modifications. Briefly, a single pneumococcal colony from a blood plate instead of pure DNA was used as the template for PCR (40 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 74°C). The amplified products were separated on a 1%

agarose gel and banding patterns were visualized with ethidium bromide staining and UV illumination with a gel documentation system (Gel Doc 2000; Bio-Rad, UK).

Multi locus sequencing typing (MLST)

S. pneumoniae isolates were streaked on blood agar and incubated at 37°C for 18 hours. A single colony from each isolate was picked, restreaked and incubated at 37°C for 18 hours. Genomic DNA templates were prepared from a loopful of bacteria as described in the manufacturer's instructions (Qiagen Genomic DNA Kit, UK). MLST was performed as described [20]. The seven genes targeted were *aroE*, *gdh*, *gki*, *recP*, *spi*, *xpt* and *ddl*. Amplifications for all genes were carried out with approximately 0.2 µg DNA template, 250 µM (each) deoxynucleoside triphosphates,




Figure 1
BOX-PCR fingerprint patterns of invasive paediatric *S. pneumoniae* isolates collected during the PVT trial. (a) PCR fingerprint patterns generated with BOX primer. Lanes 2–10 contained serotypes found in the 9-valent vaccine (1, 4, 5, 6B, 9V, 14, 18C, 19F & 23F) respectively. Lanes 1 & 12 contained a molecular weight standard; 100-bp and 1 kb respectively. Lane 11; negative (no DNA) control. **(b)** BOX-PCR fingerprint patterns of invasive pneumococcal serotype 1 collected during the PVT trial. Lanes 2–9 & 11 contained serotypes 1 isolates. Lane 1 contained a 1 kb molecular weight standard and lane 10 a negative (no DNA) control. There are two BOX-PCR fingerprint profiles designated A and B.

Table 1: Distribution of invasive paediatric *S. pneumoniae* isolates by vaccine and non-vaccine serotypes between children randomized to receive vaccine and those randomized to receive placebo (intent-to-treat analysis).

| Serotype | No. of isolates | | |
|--------------|-----------------|------------|------------|
| | Unvaccinated | Vaccinated | Total |
| 1 | 3 | 5 | 8 |
| 2 | 1 | 0 | 1 |
| 4 | 3 | 0 | 3 |
| 5 | 10 | 1 | 11 |
| 6A | 3 | 3 | 6 |
| 6B | 4 | 1 | 5 |
| 8 | 0 | 2 | 2 |
| 9L | 5 | 0 | 5 |
| 9V | 2 | 2 | 4 |
| 12B | 0 | 1 | 1 |
| 12F | 7 | 5 | 12 |
| 14 | 17 | 3 | 20 |
| 16F | 4 | 0 | 4 |
| 18C | 1 | 0 | 1 |
| 18F | 1 | 0 | 1 |
| 19A | 6 | 6 | 12 |
| 19F | 2 | 0 | 2 |
| 20 | 0 | 1 | 1 |
| 21 | 0 | 2 | 2 |
| 22A | 1 | 1 | 2 |
| 23F | 9 | 2 | 11 |
| 29 | 0 | 1 | 1 |
| 33F | 0 | 2 | 2 |
| 35A | 0 | 2 | 2 |
| 35B | 0 | 1 | 1 |
| 38 | 2 | 0 | 2 |
| 40 | 0 | 1 | 1 |
| 45 | 1 | 0 | 1 |
| 46 | 0 | 3 | 3 |
| Total | 82 | 45 | 127 |

2.5 mM MgCl₂, 25 pmol of primers, and 1 U of *Taq* polymerase (Qiagen.) in a 25 µl reaction mixture. PCR cycling conditions were a 10 min hold at 94°C, followed by 34 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, and a final extension at 72°C for 5 min. Two µl of reaction mixtures were separated by 1.0% agarose gel electrophoresis and visualized with ethidium bromide staining and UV illumination with a gel documentation system (Gel Doc 2000; Bio-Rad, UK).

PCR products were sent to Macrogen (South Korea) for purification and DNA sequencing on both strands. Sequences were edited and complementary sense and antisense fragments were aligned using the Laser Gene DNA star 7.1 software. The sequences were submitted to the MLST database website [21] and assigned existing or novel allele type numbers and sequence type numbers defined by the database. This multi microorganism data-

base defines a novel allele type if it contains one or more nucleotide changes from existing allele sequences. Composite sequence types (STs) are assigned based on the set of allele types derived from each of the seven loci. STs were analyzed for relatedness using the eBURST v3 program [22]. Cluster analysis of allelic profiles was performed using a categorical coefficient and a graphic method called a minimum spanning tree with Bionumerics software (version 4.0; Applied Maths, Sint-Martens-Latem, Belgium).

Results

Microbiology

All 127 invasive isolates were screened for antimicrobial susceptibility by disc diffusion and MIC was detected by the E-test technique. 100% of the isolates were susceptible to cefotaxime and ampicillin, whilst susceptibility to penicillin, chloramphenicol, cotrimoxazole, and tetracycline were 97.6%, 88.8%, 80.0% and 46.4% respectively. Two isolates were resistant to three antibiotics (chloramphenicol, cotrimoxazole, and tetracycline) whereas 13 isolates were resistant to two antibiotics (tetracycline and chloramphenicol or cotrimoxazole). One child had two episodes of pneumococcal disease caused by different isolates. The isolate involved in the first episode of illness was susceptible to all antibiotics tested whereas the isolate from the second episode was resistant to tetracycline and chloramphenicol.

Serotypes, clones and vaccination status

Twenty-nine different serotypes of pneumococci were detected among 127 isolates (Table 1). Serotypes 14, 19A, 12F, 5, 23F and 1 (in descending order), were common and accounted for 58.3% of all serotypes overall. Among unvaccinated children, serotypes 14, 5, 23F, 12F, 19A and 9L (in descending order) were commonest. Overall, 59 (46.4%) of the 127 serotypes were covered by the conjugates in the PCV9 vaccine (Table 1).

The genetic structure of the 127 isolates was examined using MLST and BOX-PCR analysis. BOX analysis revealed that all the 127 isolates shared an identical or closely related profile (representative isolates depicted in figure 1) and that this analysis can differentiate between serotypes (figure 1a) and within serotypes (figures 1b). For example we observed two fingerprinting patterns (A and B) for serotype 1 isolates (figure 1b)

MLST showed that there were 72 sequence types (ST) (Table 2), 46 (64%) of which are novel, *i.e.* not found in the *S. pneumoniae* MLST database [21]. eBURST analysis using the stringent 6/7 identical loci definition, grouped these ST into 17 clonal complexes and 31 singletons indicating a large genetic diversity between the isolates (figure 2). The results of cluster analysis of all allelic profiles




Figure 2
Clustering of STs by use of the minimum spanning tree. Each circle represents an ST, and the serotype number is indicated in the circle. The area of each circle corresponds to the number of isolates. Thick, short, solid lines connect single-locus variants and thin, longer, solid lines connect double-locus variants. Each colour represents the source of isolates. **Source:** LA (lung aspirate), CSF (cerebrospinal fluid), VB (venous blood), and PE (pleural effusion).

using the minimum spanning tree are shown in figure 2. In general, STs were restricted to the same serotype (Table 2) and the results between our data set and the pneumococcal MLST database [21] were concordant.

A complete data set for BOX-PCR dendrogram, MLST, serotyping, antibiotic susceptibility pattern and the source of pneumococcal isolates used in this study are shown in the figures 3 and 4'.

New alleles obtained in this study

We discovered seven new alleles including one *aroE* (118), two *gdh* (188, 189), three *spi* (176, 178,179) and one *xpt* (241).

Discussion

One hundred and thirty-two *S. pneumoniae* isolates were recovered from vaccinated and unvaccinated children aged 2–29 months during the course of a pneumococcal

conjugate vaccine trial conducted in The Gambia of which 131 were characterized by serotyping, antibiotic susceptibility, BOX-PCR and MLST and 127 had unique MLST and/or antibiotic susceptibility pattern and were included in this study.-

There was no particular association of clones with specific presentations of invasive pneumococcal disease (data not shown) although three out of six (50%) cases of meningitis were caused by pneumococci belonging to serotype 12F with ST989. This result concurs with findings in Northern Ghana [23] and Niger where serotype 12F ST989 isolates have been detected in patients with meningitis. Serotype 12F ST989 isolates have also been identified in nasopharyngeal carriers in a village in Kenya [24] and in Qatar [25]. Similarly, a SLV of ST989, serotype 12B ST2211, was responsible for a case of meningitis in Niger [25].




Figure 3
Dendrogram showing the relatedness among the STs and serotypes of *S. pneumoniae* by use of UPGMA from BOX-PCR. Notes: Antimicrobial patterns: pen (penicillin G); amp (ampicillin), chlo (chloramphenicol), cotr (cotrimoxazole tetr (tetracycline) and cefo (cefotaxime); Source: LA (lung aspirate), CSF (cerebrospinal fluid), VB (venous blood), and PE (pleural effusion).




Figure 4
Dendrogram showing the relatedness among the STs and serotypes of *S. pneumoniae* by use of UPGMA from BOX-PCR. Notes: Antimicrobial patterns: pen (penicillin G); amp (ampicillin), chlo (chloramphenicol), cotr (cotrimoxazole tetr (tetracycline) and cefo (cefotaxime); Source: LA (lung aspirate), CSF (cerebrospinal fluid), VB (venous blood), and PE (pleural effusion).

Table 2: Molecular characterisation of paediatric *S. pneumoniae* serotypes by MLST

| Serotype | ST | Allelic profile | | | | | | | |
|--------------|--------------|-----------------|------------|------------|-------------|------------|------------|------------|----|
| | | <i>aroE</i> | <i>gdh</i> | <i>gki</i> | <i>recP</i> | <i>spi</i> | <i>xpt</i> | <i>ddl</i> | |
| Serotype 1 | 618 | 13 | 8 | 4 | 1 | 7 | 19 | 14 | |
| | 3336 | 13 | 8 | 4 | 1 | 7 | 19 | 161 | |
| Serotype 2 | 3314 | 2 | 13 | 4 | 1 | 6 | 6 | 6 | |
| Serotype 4 | 1469 | 8 | 88 | 103 | 18 | 46 | 142 | 161 | |
| | 3304 | 1 | 5 | 1 | 1 | 15 | 1 | 14 | |
| Serotype 5 | 289 | 16 | 12 | 9 | 1 | 41 | 33 | 33 | |
| | 3338 | 16 | 12 | 9 | 1 | 4 | 33 | 9 | |
| | 3404 | 16 | 12 | 9 | 1 | 176 | 33 | 33 | |
| | 3313 | 2 | 12 | 9 | 10 | 17 | 1 | 33 | |
| Serotype 6A | 3339 | 16 | 12 | 9 | 1 | 41 | 33 | 9 | |
| | 912 | 6 | 57 | 34 | 28 | 7 | 1 | 9 | |
| | 913 | 6 | 57 | 83 | 28 | 7 | 19 | 9 | |
| | 1737 | 6 | 57 | 34 | 28 | 6 | 1 | 9 | |
| | 2157 | 1 | 8 | 1 | 5 | 42 | 60 | 14 | |
| Serotype 6B | 3324 | 7 | 8 | 1 | 5 | 42 | 60 | 14 | |
| | 385 | 7 | 6 | 1 | 2 | 6 | 1 | 14 | |
| | 3342 | 60 | 82 | 4 | 5 | 42 | 122 | 28 | |
| Serotype 8 | 3323 | 7 | 6 | 1 | 35 | 6 | 1 | 14 | |
| | 3325 | 7 | 9 | 15 | 11 | 93 | 58 | 70 | |
| Serotype 9L | 3406 | 7 | 9 | 15 | 11 | 178 | 58 | 70 | |
| | 1735 | 6 | 5 | 2 | 5 | 36 | 1 | 5 | |
| Serotype 9V | 3305 | 1 | 8 | 4 | 15 | 16 | 3 | 31 | |
| | 3317 | 6 | 5 | 2 | 6 | 36 | 1 | 5 | |
| | 2179 | 15 | 17 | 4 | 4 | 6 | 1 | 17 | |
| Serotype 12F | 3337 | 15 | 17 | 4 | 16 | 6 | 20 | 161 | |
| | 3409 | 15 | 17 | 4 | 4 | 179 | 20 | 17 | |
| Serotype 12B | 989 | 12 | 5 | 89 | 8 | 6 | 112 | 14 | |
| Serotype 14 | 3335 | 12 | 5 | 89 | 8 | 6 | 25 | 14 | |
| | 63 | 2 | 5 | 36 | 12 | 17 | 21 | 14 | |
| | 3320 | 6 | 60 | 1 | 5 | 27 | 20 | 6 | |
| | 3312 | 2 | 5 | 89 | 12 | 27 | 21 | 14 | |
| | 3321 | 6 | 60 | 4 | 5 | 27 | 20 | 6 | |
| | 3333 | 10 | 60 | 4 | 12 | 15 | 112 | 6 | |
| | 3310 | 2 | 5 | 36 | 12 | 27 | 21 | 14 | |
| | 3318 | 6 | 9 | 4 | 5 | 27 | 20 | 6 | |
| | 3322 | 6 | 60 | 4 | 5 | 27 | 38 | 6 | |
| | 3309 | 2 | 5 | 36 | 12 | 17 | 38 | 14 | |
| | 3311 | 2 | 5 | 89 | 12 | 17 | 21 | 14 | |
| | Serotype 16F | 3341 | 23 | 12 | 4 | 1 | 6 | 12 | 74 |
| | | 3407 | 23 | 189 | 4 | 12 | 43 | 4 | 74 |
| | | 3408 | 23 | 189 | 4 | 12 | 15 | 241 | 74 |
| 3419 | | 6 | 189 | 4 | 12 | 15 | 241 | 74 | |
| Serotype 18C | 1233 | 10 | 11 | 34 | 16 | 15 | 1 | 145 | |
| Serotype 18F | 2425 | 10 | 5 | 34 | 16 | 36 | 142 | 31 | |
| Serotype 19A | 202 | 8 | 16 | 19 | 15 | 6 | 40 | 26 | |
| | 847 | 7 | 11 | 4 | 1 | 6 | 112 | 14 | |
| | 2174 | 7 | 16 | 8 | 8 | 6 | 142 | 14 | |
| | 3327 | 7 | 11 | 4 | 10 | 6 | 112 | 14 | |
| | 3326 | 7 | 11 | 4 | 1 | 6 | 112 | 15 | |
| | 3330 | 7 | 16 | 4 | 1 | 6 | 112 | 14 | |
| | 3315 | 5 | 6 | 1 | 2 | 6 | 1 | 5 | |
| | 3331 | 7 | 16 | 8 | 8 | 4 | 142 | 14 | |
| | 3307 | 2 | 5 | 4 | 10 | 6 | 1 | 14 | |
| Serotype 19F | 3340 | 16 | 16 | 19 | 1 | 6 | 20 | 33 | |
| | 1734 | 5 | 31 | 8 | 1 | 27 | 1 | 31 | |
| Serotype 20 | 3316 | 6 | 5 | 2 | 5 | 67 | 49 | 18 | |

In this study, we found twenty-nine different serotypes corresponding to seventy-two MLST types (sequence types). MLST is the definitive, internationally accepted method for monitoring the spread of clones through the pneumococcal population [20,21,26]. Our data showed that serotype and genotype distribution varied considerably in vaccinated and unvaccinated children suggesting a high degree of fluidity in the pneumococcal population dynamics (figure 2).

Although the 9-valent vaccine used in our trial contained glycoproteins for serotypes 1 and 9V, pneumococci of these serotypes caused a small number of cases of invasive disease with no reduction in cases in vaccinated children. For example, 4 vaccinated children (from whom 5 isolates were obtained – Table 1) had invasive disease due to a serotype 1 infection compared with 2 unvaccinated children (from whom 3 isolates were obtained – Table 1). There was no clustering of cases of serotype 1 in either vaccinated or unvaccinated groups over time during the period 2002–2004. The very small number of serotype 1 and 9V cases detected precludes precise estimation of serotype-specific efficacy for these two serotypes but these findings raise the possibility that efficacy was lower against serotypes 1 and 9V than against other vaccine-type serotypes, despite the fact that the vaccine elicited strong immune responses, as measured by ELISA, for all serotypes contained in the 9-valent vaccine, including serotypes 1 and 9V (data not shown). All but one of the seven serotype 1 isolates in our study had the same genotype, ST 618. One of the isolates, from an unvaccinated child, had a novel ST (ST3336) which is a SLV of ST 618. ST 618 and its single and double locus variant have recently been observed to cause meningitis in Ghana, Burkina Faso and Egypt [25]. Furthermore, ST618 belongs to the same clonal complex (ST 217) of serotype 1 that has caused an outbreak of meningitis in Northern Ghana [23], indicating a dominant West African clone. The ST217 hypervirulent clonal complex is typical of lineage B serotype 1 pneumococci that are predominant within Africa and Israel [26]. A lower efficacy for serotype 1 and 9V could be explained by heterogeneity or intraspecies variations among these invasive pneumococci.

Isolates belonging to the same genotype (clone) can express different types of capsular polysaccharide through horizontal recombination of pneumococcal DNA by natural transformation [20]. This phenomenon, capsular switching, leads to the emergence of a new clone expressing a different capsule [17]. There was no direct evidence of capsular switching within our isolates. However, comparative analysis of our serotype and MLST results with those published in the MLST database showed that some genotypes found in our isolates express different serotypes in other areas. For example, we found genotype ST63 to be

Table 2: Molecular characterisation of paediatric *S. pneumoniae* serotypes by MLST (Continued)

| | | | | | | | | |
|--------------|------|-----|-----|----|----|----|----|----|
| Serotype 21 | 1746 | 10 | 13 | 4 | 16 | 15 | 1 | 6 |
| Serotype 22 | 910 | 5 | 5 | 6 | 5 | 9 | 17 | 19 |
| | 2214 | 5 | 5 | 4 | 4 | 11 | 19 | 18 |
| Serotype 23F | 802 | 10 | 13 | 53 | 1 | 72 | 38 | 31 |
| | 1526 | 7 | 13 | 8 | 6 | 25 | 1 | 8 |
| | 3343 | 7 | 13 | 53 | 1 | 72 | 38 | 14 |
| | 3410 | 118 | 8 | 4 | 12 | 72 | 19 | 5 |
| Serotype 29 | 2942 | 12 | 111 | 34 | 84 | 19 | 83 | 6 |
| Serotype 33 | 445 | 2 | 5 | 29 | 5 | 42 | 3 | 18 |
| | 3308 | 2 | 5 | 29 | 18 | 13 | 3 | 18 |
| Serotype 35B | 3329 | 7 | 13 | 4 | 8 | 6 | 20 | 18 |
| | 3328 | 7 | 13 | 4 | 8 | 6 | 1 | 18 |
| Serotype 38 | 310 | 1 | 43 | 41 | 18 | 13 | 49 | 6 |
| | 3306 | 1 | 43 | 41 | 18 | 13 | 49 | 5 |
| Serotype 45 | 3332 | 8 | 15 | 89 | 1 | 19 | 1 | 6 |
| Serotype 46 | 3334 | 12 | 5 | 53 | 8 | 7 | 27 | 14 |

serotype 14 and associated with bacteremia and pneumonia (figure 2) and ST63 serotype 14 is associated with meningitis in Niger [27]. Elsewhere, ST63 has been found to express serotype 15A, 19A and 23F capsular polysaccharides [25], suggesting that ST63 has a high propensity for capsular switching. ST912 expressing serotype 9V capsular polysaccharide has previously been isolated from a carrier in The Gambia [25] but in this study we found ST912 expressing serotype 6A polysaccharide. Similarly, ST2179 expressing serotype 6A capsular polysaccharide has previously been isolated from a Gambian carrier [25] while in this study we found ST2179 expressing serotype 9V polysaccharide and causing invasive disease, suggesting capsular switching. Similarly, ST2174 expressing a serotype 23F capsule has previously been isolated from a carrier in The Gambia [25] but in this study we found ST2174 expressing serotype 19A capsular polysaccharide again suggesting capsular switching. This is plausible as cluster analysis from our data shows that serotype 19A and 23F are genetically linked (figure 2). Although our data is suggestive that capsular switching can occur naturally, a large dataset will be required to show the impact of conjugate vaccination on this process. We have recently set up nasopharyngeal pneumococcal carriage studies in 21 villages in The Gambia to address this question [28].

The use of PCV has the potential to reduce substantially the number of drug-resistant pneumococcal infections [29]. Antimicrobial resistance in pneumococci is closely linked to serotype and genotype. Although we found no penicillin resistant isolates in this study, there is evidence from The Gambia that isolates of vaccine serotype have significantly higher intermediate resistance to penicillin than those of non-vaccine serotype ($p < 0.01$) [28]. Similarly, isolates of 9-valent serotype were less likely to be resistant to tetracycline than those of a non-vaccine serotype (39.0% vs. 52.6%; $p < 0.05$). In contrast, isolates of non-vaccine serotype were more likely to be resistant to

chloramphenicol ($p < 0.0001$). Interestingly, we identified two serotype 6B isolates with ST385 and ST3323 which were-resistant to three antibiotics; chloramphenicol, cotrimoxazole and tetracycline. ST385 and ST3323 are also SLV and DLV respectively to ST273. ST273 is known to be a major pandemic antimicrobial-resistant clone, Greece 6B-22 [30,31] of pneumococci as defined by the pneumococcal molecular epidemiology network.

Conclusion

Plans are being developed for the introduction of pneumococcal conjugate vaccines into the routine immunization programmes of several countries in Africa. We conclude that in order to assess the impact of this intervention on the prevalence of antimicrobial resistance in strains of *S. pneumoniae* causing IPD and on the propensity of PCV to cause serotype replacement it will be necessary to monitor the antimicrobial susceptibility of *S. pneumoniae* isolates from cases of IPD in parallel with serotypic and genotypic characterization before and after the introduction of these programmes.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MA and RA conceived the study and wrote the paper with GE, FC and BMG. MA, HD-A, JO'C and VP performed PCR, sequence reactions, edited and aligned DNA sequences for MLST analysis. EB cultured and identified bacteria isolates from clinical samples. GE, BO, CO, AV, SMAZ and FC participated in field and clinical aspects of the study. TA was involved in statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge Ishrat Hakeem, Ebou Mbowe, Lamin Juwara, Mark Saaka, Ousman Secka and Pauline Sambou for technical assistance. We also acknowledge the use of the *S. pneumoniae* MLST database [25] which is housed at Imperial College, London.

The Gambia Pneumococcal Vaccine Trial was funded by grants from MRC (UK), the National Institute of Allergy and Infectious Diseases at the USA National Institutes of Health through contract N01-AI-25477; WHO through contract V23/181/127; the Children's Vaccine Program at PATH; and US Agency for International Development

References

- Shann F: **Etiology of severe pneumonia in children in developing countries.** *Pediatr Infect Dis* 1986, **5(2)**:247-252.
- Greenwood B: **The epidemiology of pneumococcal infection in children in the developing world.** *Philos Trans R Soc Lond B Biol Sci* 1999, **354(1384)**:777-785.
- Scott J: **The preventable burden of pneumococcal disease in the developing world.** *Vaccine* 2007, **25(13)**:2398-2405.
- Adegbola R, Falade A, Sam B, Aidoo M, Baldeh I, Hazlett D, Whittle H, Greenwood B, Mulholland E: **The etiology of pneumonia in malnourished and well-nourished Gambian children.** *Pediatr Infect Dis J* 1994, **13(11)**:975-982.

5. O'Dempsey T, McArdle T, Lloyd-Evans N, Baldeh I, Lawrence B, Secka O, Greenwood B: **Pneumococcal disease among children in a rural area of west Africa.** *Pediatr Infect Dis J* 1996, **15(5)**:431-437.
6. Usen S, Adegbola R, Mulholland K, Jaffar S, Hilton S, Oparaugo A, Omosigbo C, Lahai G, Corrah T, Palmer A, Schneider G, Weber M, Greenwood B: **Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia.** *Pediatr Infect Dis J* 1998, **17**:23-28.
7. Enwere G, Biney E, Cheung Y, Zaman S, Okoko B, Oluwalana C, Vaughan A, Greenwood B, Adegbola R, Cutts F: **Epidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The Gambia.** *Pediatr Infect Dis J* 2006, **25**:700-705.
8. Wall R, Corrah P, Mabey D, Greenwood B: **The etiology of lobar pneumonia in the Gambia.** *Bull World Health Organ* 1986, **64(4)**:553-558.
9. Forgie I, O'Neill K, Lloyd-Evans N, Leinonen M, Campbell H, Whittle H, Greenwood B: **Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital.** *Pediatr Infect Dis J* 1991, **10(1)**:42-47.
10. Berkley J, Lowe B, Mwangi I, Williams T, Bauni E, Mwarumba S, Ngetsu C, Slack MP, Njenga S, Hart CA, Maitland K, English M, Marsh K, JA S: **Bacteremia among children admitted to a rural hospital in Kenya.** *N Engl J Med* 2005, **352(1)**:39-47.
11. Berman S: **Otitis media in children.** *N Engl J Med* 1995, **332(23)**:1560-1565.
12. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K: **The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population.** *Aids* 1998, **12(16)**:2177-2184.
13. Madhi S, P K, Madhi A, Wasas A, Klugman K: **Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children.** *Pediatr Infect Dis J* 2000, **19(12)**:1141-1147.
14. Park I, Pritchard D, Cartee R, Brandao A, Brandileone M, Nahm M: **Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae.** *J Clin Microbiol* 2007, **45(4)**:1225-1233.
15. Hausdorff W, Bryant J, Paradiso PR, GR S: **Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use.** *Clin Infect Dis* 2000, **30(1)**:100-121.
16. Cutts F, Zaman S, Enwere G, Jaffar S, Levine O, Okoko J, Oluwalana C, Vaughan A, Obaro S, Leach A, McAdam K, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce N, Greenwood B, Adegbola R: **Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.** *Lancet* 2005, **365**:1139-1146.
17. Gertz RJ, McEllistrem M, Boxrud D, Li Z, Sakota V, Thompson TF, R R, Besser J, Harrison L, Whitney C, Beall B: **Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction.** *J Clin Microbiol* 2003, **41**:4194-4216.
18. [<http://www.ukneqas.org.uk>].
19. van Belkum A, Sluijter M, de Groot R, Verbrugh H, Hermans P: **Novel BOX repeat PCR assay for high-resolution typing of Streptococcus pneumoniae strains.** *J Clin Microbiol* 1996, **34**:1176-1179.
20. Coffey T, Enright M, Daniels M, Morona J, Morona R, Hryniewicz W, Paton J, Spratt B: **Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae.** *Mol Microbiol* 1998, **27**:73-83.
21. Aanensen D, Spratt B: **The multilocus sequence typing network: mlst.net.** *Nucleic Acids Res* 2005, **33**:W728-W733.
22. [<http://eburst.mlst.net/>].
23. Leimkugel J, Adams Forgor A, Gagneux S, Pfluger V, Flierl C, Awine E, Naegeli M, Dangy J, Smith T, Hodgson A, Pluschke G: **An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics.** *J Infect Dis* 2005, **192**:192-199.
24. Medina M, Greene C, Gertz R, Facklam R, Jagero G, Hamel M, Shi Y, Slutsker L, Feikin D, B B: **Novel antibiotic-resistant pneumococcal strains recovered from the upper respiratory tracts of HIV-infected adults and their children in Kisumu, Kenya.** *Microb Drug Resist* 2005, **11**:9-17.
25. [<http://spneumoniae.mlst.net/>].
26. Brueggemann A, Peto T, Crook D, Butler J, Kristinsson K, Spratt B: **Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.** *J Infect Dis* 2004, **190**:1203-1211.
27. Yaro S, Lourd M, Traore Y, Njanpop-Lafourcade B, Sawadogo A, Sangare L, Hien A, Ouedraogo M, Sanou O, Parent du Chatelet I, Koeck J, BD G: **Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso.** *Clin Infect Dis* 2006, **43**:693-700.
28. Adegbola R, Hill P, Secka O, Ikumapayi U, Lahai G, Greenwood B, Corrah T: **Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996-2003.** *Trop Med Int Health* 2006, **11**:1128-1135.
29. Kyaw M, Lynfield R, Schaffner W, Craig A, Hadler J, Reingold A, Thomas A, Harrison L, Bennett N, Farley M, Facklam R, Jorgensen J, Besser J, Zell E, Schuchat A, Whitney C, Active Bacterial Core Surveillance of the Emerging Infections Program Network: **Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae.** *N Engl J Med* 2006, **354**:1455-1463.
30. Munoz R, Coffey T, Daniels M, Dowson C, Laible G, Casal J, Hakenbeck R, Jacobs M, Musser J, Spratt B, Tomas A: **Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.** *J Infect Dis* 1991, **64**:302-306.
31. Coffey T, Dowson C, Daniels M, Zhou J, Martin C, Spratt B, Musser J: **Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae.** *Mol Microbiol* 1991, **5**:2255-2260.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/8/81/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

